Asia news, travel and food

Home » China’s Subsidies Fail to Reverse Birth Plunge as Population Shrinks

China’s Subsidies Fail to Reverse Birth Plunge as Population Shrinks

By

–

China's Subsidies Fail to Reverse Birth Plunge as Population Shrinks

China’s population fell to 1.404 billion in 2025, a decline of three million from the year before, as deaths continued to outpace births for the third consecutive year, according to official data. The total fertility rate dropped below 1.0, the lowest level since the founding of the People’s Republic of China in 1949, and the old-age dependency ratio recently exceeded the child dependency ratio for the first time, marking a structural shift toward an older society.

The Legacy of the One-Child Policy

The current contraction has roots in the one-child policy enforced from 1979 to 2015, which limited urban families to one child and rural families to two. That measure, described by scholars as the most far-reaching population control effort in modern history, engineered a rapid decline in fertility that persisted long after the policy was relaxed. Researchers at East Asia Forum note that the policy shaped deep-seated beliefs about ideal family size, norms that cannot be reversed quickly by new incentives. Marriage rates are also declining, which officials said poses an ominous trajectory for future birth rates.

Why Pronatalist Incentives Have Stalled

Beijing has pivoted to subsidies for childcare, housing assistance, and state-backed pro-birth campaigns. Yet these measures have yet to produce clear results, according to state and international reports. Analysts argue that simply offering cash transfers or parental leave does not reduce the labor of care itself, which typically falls on the parent with the lower opportunity cost — usually women. The account indicates that effective policy would need to address the gender inequality in sharing household work rather than only increasing total household resources. Financial constraints also bind; many couples already support elderly parents, a commitment that new subsidies do not instantly alleviate.

Automation and Biotech as Economic Responses

With the labor force shrinking, the economic strategy is shifting toward automation and biotechnology. China’s value-added industrial output rose 4.8 percent year-on-year in October 2026, suggesting manufacturing resilience despite demographic headwinds. In life sciences, Chinese firms are moving up the value chain. Chinese biotechnology assets accounted for 56 percent of global licensing deal value in 2026, up from 10 percent in 2021, generating approximately US$59 billion and surpassing U.S. counterparts. BeOne’s blood-cancer therapy Brukinsa generated US$3.9 billion in annual sales in 2025, illustrating the commercial reach of domestically developed treatments. According to the Biotechnology Innovation Organization, aging populations change the structure of demand, turning healthcare into a mass-market opportunity that directs capital and talent toward innovation.

Sources

Photo: Krzysztof Kowalik / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Asia News

Asia Travel & Food

Politics

World News